https://www.selleckchem.com/GSK-3.html
004) or patients with primary tumor burden beyond the Milan criteria (P = .004). Multivariate analysis showed that treatment allocation was identified as an independent prognostic factor for PRS. CONCLUSION Compared with RFA, RHR provided a survival advantage for recurrent HCC, especially for patients who relapsed within 2 years and those with primary tumor burden beyond the Milan criteria. © 2020 The Authors. Cancer Medicine published by John Wiley Sons Ltd.The rising concerns of the recurrence and bone deficiency in surgical treatment of m
Like
Comment
Share
